A carregar...
The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery
The high frequency of RAS mutations in human cancers (33%) has stimulated intense interest in the development of anti-Ras inhibitors for cancer therapy. Currently, the major focus of these efforts is centered on inhibitors of components involved in Ras downstream effector signaling. In particular, m...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3128631/ https://ncbi.nlm.nih.gov/pubmed/21779498 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1947601911407329 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|